JAK/STAT signaling as a key regulator of ferroptosis: mechanisms and therapeutic potentials in cancer and diseases

被引:0
|
作者
Dai, Yimeng [1 ]
Cui, Chunguo [2 ]
Jiao, Dan [3 ]
Zhu, Xuewei [4 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Radiol, Changchun, Peoples R China
[2] Jilin Univ, China Japan Union Hosp, Dept Breast Surg, Changchun, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Ultrasound, Changchun, Peoples R China
[4] Jilin Univ, China Japan Union Hosp, Dept Otolaryngol, Changchun, Peoples R China
关键词
Ferroptosis; JAK/STAT signaling; JAK2; STAT3; STAT1; STAT6; Therapy; INJURY; IRON; AXIS;
D O I
10.1186/s12935-025-03681-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ferroptosis is a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation, playing a critical role in various diseases, including cancer, neurodegeneration, and tissue damage. This study reviews the intricate relationship between ferroptosis and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, highlighting its regulatory functions across multiple biological processes. Dysregulation of the JAK/STAT pathway is implicated in promoting or inhibiting ferroptosis, depending on the context. JAK2 promotes ferroptosis by activating STAT proteins, modulating the expression of key regulators like SLC7A11 and GPX4, and influencing iron homeostasis through pathways such as ferritinophagy and hepcidin regulation. STAT1 activation primarily enhances ferroptosis through the suppression of cystine-glutamate antiporter (System Xc-), leading to glutathione depletion and lipid peroxidation, contributing to cell death in conditions like Sjogren's syndrome and age-related macular degeneration. In contrast, STAT3 plays a protective role by upregulating SLC7A11 and GPX4, which inhibits ferroptosis and promotes cell survival, particularly in cancers such as hepatocellular carcinoma, prostate cancer, and renal cell carcinoma. This study also discusses STAT6's involvement in ferroptosis suppression in diseases like asthma and lung injury by regulating antioxidant defenses. Furthermore, the review explores potential therapeutic strategies targeting the JAK/STAT pathway to manipulate ferroptosis for disease treatment. In cancer therapy, modulating this pathway can enhance the effectiveness of ferroptosis inducers, offering promising avenues to overcome drug resistance. Additionally, the interplay between ferroptosis and JAK/STAT signaling in immune responses, oxidative stress, and lipid metabolism underscores its significance in disease progression and therapeutic intervention. By exploring these mechanisms, this study provides insights into the development of novel treatments targeting ferroptosis through JAK/STAT modulation, with implications for cancer, inflammatory diseases, and neurodegenerative conditions.
引用
收藏
页数:40
相关论文
共 50 条
  • [21] JAK-STAT signaling as an ARDS therapeutic target: Status and future trends
    Zhang, Yuanteng
    Gao, Zizheng
    Jiang, Feng
    Yan, Hao
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Xu, Zhifei
    Yang, Xiaochun
    BIOCHEMICAL PHARMACOLOGY, 2023, 208
  • [22] JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications
    Rah, Bilal
    Farhat, Nada Mazen
    Hamad, Mawieh
    Muhammad, Jibran Sualeh
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3147 - 3157
  • [23] JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications
    Bilal Rah
    Nada Mazen Farhat
    Mawieh Hamad
    Jibran Sualeh Muhammad
    Clinical and Experimental Medicine, 2023, 23 : 3147 - 3157
  • [24] Ferroptosis in cancer: Mechanisms, therapeutic strategies, and clinical implications
    Mamaghani, Mina Pourhabib
    Mousavikia, Seyedeh Nasibeh
    Azimian, Hosein
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 269 : 155907
  • [25] FSP1-mediated ferroptosis in cancer: from mechanisms to therapeutic applications
    Gao, Ran
    Wang, Jinge
    Huang, Jingjing
    Wang, Tong
    Guo, Lingfeng
    Liu, Wenlu
    Guan, Jialu
    Liang, Desen
    Meng, Qinghui
    Pan, Huayang
    APOPTOSIS, 2024, 29 (7-8) : 1019 - 1037
  • [26] Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies
    Oxley, Madisyn
    Francis, Heather
    Sato, Keisaku
    SEMINARS IN LIVER DISEASE, 2023, 43 (01) : 24 - 30
  • [27] Moscatilin Induces Ferroptosis in Clear Cell Renal Cell Carcinoma via the JAK-STAT Signaling Pathway
    Chen, Pei
    Yang, Jin
    Chen, Lin
    Liu, Chenhuan
    Li, Zhihao
    Long, Xiaoming
    Wu, Jinbang
    Wu, Bo
    Wu, Jianjun
    CHEMICAL BIOLOGY & DRUG DESIGN, 2025, 105 (03)
  • [28] Exploring the Updated Roles of Ferroptosis in Liver Diseases: Mechanisms, Regulators, and Therapeutic Implications
    Ge, Ting
    Wang, Yang
    Han, Yiwen
    Bao, Xiaofeng
    Lu, Chunfeng
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2024, : 1445 - 1464
  • [29] Editorial: Ferroptosis as new therapeutic targets in cancer: From molecular mechanisms to therapeutic opportunities
    Chen, Jian
    Chen, Xu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] E-cadherin acts as a positive regulator of the JAK-STAT signaling pathway during Drosophila oogenesis
    Mallart, Charlotte
    Chalvet, Fabienne
    Netter, Sophie
    Torres, Alba Yurani
    Poidevin, Mickael
    Montagne, Jacques
    Pret, Anne-Marie
    Malartre, Marianne
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10